Biography
 |
William J. Gradishar, MD, FACP Professor of Medicine Division of Hematology/Oncology Northwestern Medical Faculty Foundation Northwestern University Medical School Feinberg School of Medicine Chicago, IL |
William J. Gradishar received his medical degree from the University of Illinois Abraham School of Medicine in Chicago, IL. He completed his residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago, and a fellowship in medical oncology at the University of Chicago. Dr. Gradishar is now a Professor of Medicine in the Division of Hematology and Medical Oncology, Department of Medicine, at the Feinberg School of Medicine at Northwestern University in Chicago, IL, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He also serves as Director of Breast Medical Oncology, Associate Director of the Lynn Sage Comprehensive Breast Program, and Program Director of Northwestern University’s Hematology/Oncology fellowship training program.
Dr. Gradishar’s research focuses on the development of novel therapeutics for the treatment of breast cancer.
He has published extensively in the area of breast cancer therapeutics, with a focus on new therapeutic strategies and breast cancer management. Dr. Gradishar is the editor-in-chief of Journal Watch Oncology-Hematology. He also serves on the editorial boards of Clinical Cancer Research, Clinical Breast Cancer, and Breast Disease: A Year Book Quarterly.
A fellow of the American College of Physicians, Dr. Gradishar is also a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. He has been active in ASCO as the previous chair of the Oncology Training Committee and Cancer Communication Committee. He is a member of the Breast Cancer Core Committee of the Eastern Cooperative Oncology Group, the Committee on Cancer of the American College of Surgeons, the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, and the NCCN Breast Cancer Prevention Panel. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the FDA.